influenza Archives

In Depth 11 Jul 2023

AIS Biotech: startup employs carbohydrates to fight the flu

Keen on discovering novel ways to tackle viral infections, AIS Biotech, a French company based in the Alps, aims to combat influenza, more commonly known as the flu, by leveraging the medicinal promise behind glycobiotechnology. A field that has been gaining momentum over the past decade, glycobiotechnology is the study of complex carbohydrates which has […]

July 11, 2023 - 6 minutesmins - By Roohi Mariam Peter

News and Trends 29 Jun 2023

AI program finds multiple influenza drug targets

Poolbeg Pharma, a clinical-stage biopharma company focusing on infectious and other prevalent diseases, has announced a breakthrough in its world-first influenza Artificial Intelligence (AI) Programme working with the company CytoReason. Poolbeg’s disease progression data from influenza human challenge trials combined with CytoReason’s broad repositories of curated disease data were analyzed using CytoReason’s AI-led platform. The […]

June 29, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 26 Apr 2023

aVaxziPen’s needle-free vaccine yields positive data across multiple diseases

aVaxziPen, a biotech company developing a novel needle-free vaccine delivery platform, presented data at the World Vaccine Congress (WVC) in Washington, U.S., recently. The company presented a poster entitled, “Needle-free, injectable solid dose vaccine delivery generates equivalent immune response with different antigens and animal models.” The company said immunogenicity data from four in vivo models […]

April 26, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 7 Feb 2023

AAHI bags $9.9M to develop nasal spray influenza RNA vaccine

The Access to Advanced Health Institute (AAHI) has been awarded a project agreement worth up to $9.9 million through the Medical CBRN Defense Consortium (MCDC) Other Transaction Authority (OTA) to develop a prototype intranasal bivalent influenza RNA vaccine candidate. The candidate will be based on AAHI’s self-amplifying RNA (saRNA) platform, which targets both pandemic A(H5N1) […]

February 7, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 17 Jan 2023

Poolbeg expands POLB 001 into oncology

Poolbeg Pharma has announced the strategic expansion of POLB 001 into oncology. POLB 001 is a strain agnostic, small molecule immunomodulator being studied to address the unmet medical need for a treatment for severe influenza. While investigating the role of cytokine release syndrome (CRS) in severe influenza, Poolbeg discovered data specific to the overt immune […]

January 17, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 13 Dec 2022

Poolbeg influenza trial successfully completed

Poolbeg Pharma has received initial results having completed its lipopolysaccharide (LPS) human challenge clinical trial for POLB 001, a viral strain agnostic, small molecule immunomodulator being developed to address the unmet medical need for severe influenza. The study showed no further clinical activity is required to complete the objectives of the trial, bringing the recruitment […]

December 13, 2022 - 3 minutesmins - By Jim Cornall

Startup Scout 21 Nov 2022

Osivax is designing future-proof influenza and Covid vaccines

Viruses causing influenza and COVID-19 continually evolve to escape our vaccine protections. The French firm Osivax is developing vaccines that are harder for the viruses to evade. Many life-saving vaccines have been developed and approved to protect against viral infections including COVID-19 and influenza. Commercially available vaccines typically activate the production of antibodies against fragments […]

November 21, 2022 - 5 minutesmins - By Jonathan Smith

News and Trends 3 Nov 2022

Virax Biolabs introduces flu, Covid-19 and RSV rapid test kits

Rapid test kits that can accurately identify infections related to respiratory syncytial virus (RSV), influenza and Covid-19 can deliver results in 15 minutes. UK-based Virax Biolabs, a biotech company focused on the prevention, detection and diagnosis of viral diseases announced today (November 3) the distribution of a tripe virus antigen rapid test kit has been […]

November 3, 2022 - 2 minutesmins - By Liza Laws

News and Trends 4 Oct 2022

Patents granted for Poolbeg Pharma influenza and respiratory virus infections treatments

Poolbeg Pharma has been granted patents by the US Patent and Trademark Office (USPTO) for POLB 001, a small molecule immunomodulator for the treatment of severe influenza and POLB 002, a first-in-class, intranasally administered RNA-based immunotherapy for respiratory virus infections. POLB 001 The USPTO granted a patent for the majority of Poolbeg’s claims around the […]

October 4, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 16 Aug 2022

Pneumagen embarks on phase 2 proof of concept influenza study

Biotech company Pneumagen says the first person has been dosed in its phase 2 controlled human infection challenge study. Its product, Neumifil, is an intranasal, broad-spectrum antiviral treatment to prevent or, if infected, reduce and manage, viral respiratory tract infections. The phase 2 trial is a single center, randomized, double-blinded, placebo-controlled study evaluating two dose […]

August 16, 2022 - 2 minutesmins - By Jim Cornall

Roche announces Xofluza approval and new Elecsys IGRA SARS-CoV-2 test

News and Trends 15 Aug 2022

Roche announces influenza drug approval and new COVID test

Roche has announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Xofluza (baloxavir marboxil) for the treatment of acute uncomplicated influenza in otherwise healthy children aged five to less than 12 years of age who have been symptomatic for no more than 48 hours. This marks […]

August 15, 2022 - 6 minutesmins - By Jim Cornall

News and Trends 22 Jul 2022

Beyond Biotech podcast 6: Mogrify, +ND Capital, Poolbeg Pharma

On this week’s podcast, our guests are Jeremy Skillington, CEO of Poolbeg Pharma; Dani Bach, and Eric Moessinger, both partners at +ND Capital; and Louise Modis, chief scientific officer at Mogrify. Poolbeg Pharma gets approval for severe influenza drug trial Poolbeg Pharma, a clinical stage infectious disease pharmaceutical company, has received ethics and competent authority […]

July 22, 2022 - 7 minutesmins - By Jim Cornall

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us